HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NDI Notifications For CBD ‘Excluded’ On Arrival But US FDA Still Explains Where Safety Evidence Fails

Executive Summary

CFSAN Office of Dietary Supplement Programs tells Charlotte’s Web and Irwin Naturals that not providing sufficient evidence of a reasonable assumption of safety for an NDI's intended use wasn’t the only reason each notification was rejected.

You may also be interested in...



Welch Leads US FDA’s Dietary Supplement Office

Center for Food Safety and Applied Nutrition says Cara Welch selected to fill Office of Dietary Supplement Programs director post. She’ll move up from ODSP deputy director on 14 March.

HempFusion Publishes CBD GRAS As Food For Thought On NDI Notification It's Ready To Serve

Denver firm recently announced self-affirmed GRAS for proprietary hemp-derived CBD extract. “I have access now to food, beverage and I can add to a dietary supplement my extract as a food additive ingredient,” says CEO Jason Mitchell. While GRAS is a US regulatory pathway for food, currently none is available for lawful use of hemp-derived ingredients in supplements.

Naturopath, Regulatory Expert MacKay Returns To DC As CHPA’s Supplement Industry Strategy Chief

Consumer Healthcare Products Association names Duffy MacKay as its first senior VP for dietary supplements. Former CRN executive moves from CV Sciences back into trade group world.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel